BIOMAT Database Logo BIOMAT Database Logo

[The efficacy of combined use of 1 alpha-hydroxyvitamin D3 with calcium supplements in the treatment of osteoporosis]. 1988

S Yoshikawa, and A Ohno, and K Moro, and M Matsumoto, and H Nemoto, and H Seki, and N Kaneko, and O Hosokawa, and H Ishijima
Department of Orthopaedic Surgery, University of Tsukuba, Ibaraki, Japan.

Synthetic analogue of active vitamin D metabolite, 1 alpha (OH) D3, has been widely used in the treatment of osteoporosis. However, the most effective method of treatment is yet to be established. Importance of calcium supplement to improve the calcium metabolism in osteoporosis is also reported by many authors. We have studied the combined effects of 1 alpha (OH)D3 with calcium supplement in preventing progressive decrease of bone mass in patients with osteoporosis. Sixty-six cases of postmenopausal and senile osteoporosis were divided into two groups: one treated with calcium alone 1,000 mg a day and the other treated with calcium 1,000 mg and 1 alpha (OH)D3 0.5 microgram a day, and both groups were followed for 24 months. Bone mass was evaluated by microdensitometry of the roentgenograms of the second metacarpal bone. The results revealed that the combined use of 1 alpha (OH)D3 with calcium has a significantly more favorable effect than the use of calcium alone in preventing bone loss. Therefore, 1 alpha (OH)D3 with calcium is useful in the treatment of osteoporosis. The conclusion would be further confirmed with longer term study and a more accurate method of measuring bone mass.

UI MeSH Term Description Entries
D010024 Osteoporosis Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis. Age-Related Osteoporosis,Bone Loss, Age-Related,Osteoporosis, Age-Related,Osteoporosis, Post-Traumatic,Osteoporosis, Senile,Senile Osteoporosis,Osteoporosis, Involutional,Age Related Osteoporosis,Age-Related Bone Loss,Age-Related Bone Losses,Age-Related Osteoporoses,Bone Loss, Age Related,Bone Losses, Age-Related,Osteoporoses,Osteoporoses, Age-Related,Osteoporoses, Senile,Osteoporosis, Age Related,Osteoporosis, Post Traumatic,Post-Traumatic Osteoporoses,Post-Traumatic Osteoporosis,Senile Osteoporoses
D001842 Bone and Bones A specialized CONNECTIVE TISSUE that is the main constituent of the SKELETON. The principal cellular component of bone is comprised of OSTEOBLASTS; OSTEOCYTES; and OSTEOCLASTS, while FIBRILLAR COLLAGENS and hydroxyapatite crystals form the BONE MATRIX. Bone Tissue,Bone and Bone,Bone,Bones,Bones and Bone,Bones and Bone Tissue,Bony Apophyses,Bony Apophysis,Condyle,Apophyses, Bony,Apophysis, Bony,Bone Tissues,Condyles,Tissue, Bone,Tissues, Bone
D002118 Calcium A basic element found in nearly all tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes. Coagulation Factor IV,Factor IV,Blood Coagulation Factor IV,Calcium-40,Calcium 40,Factor IV, Coagulation
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006887 Hydroxycholecalciferols Hydroxy analogs of vitamin D 3; (CHOLECALCIFEROL); including CALCIFEDIOL; CALCITRIOL; and 24,25-DIHYDROXYVITAMIN D 3. Hydroxyvitamins D,Hydroxycholecalciferol
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

S Yoshikawa, and A Ohno, and K Moro, and M Matsumoto, and H Nemoto, and H Seki, and N Kaneko, and O Hosokawa, and H Ishijima
Results of long-term treatment of osteoporosis with 1 alpha-hydroxyvitamin D3 and calcium.
June 1984, Italian journal of orthopaedics and traumatology,
S Yoshikawa, and A Ohno, and K Moro, and M Matsumoto, and H Nemoto, and H Seki, and N Kaneko, and O Hosokawa, and H Ishijima
The ultra long-term treatment of senile osteoporosis with 1 alpha-hydroxyvitamin D3.
March 1993, Bone and mineral,
S Yoshikawa, and A Ohno, and K Moro, and M Matsumoto, and H Nemoto, and H Seki, and N Kaneko, and O Hosokawa, and H Ishijima
Bone mineral and calcium metabolism before, during and after treatment of osteoporosis with 1 alpha-hydroxyvitamin D3 and calcium.
January 1982, Scandinavian journal of rheumatology,
S Yoshikawa, and A Ohno, and K Moro, and M Matsumoto, and H Nemoto, and H Seki, and N Kaneko, and O Hosokawa, and H Ishijima
Changes in bone histomorphometry and bone mineral during treatment of osteoporosis with 1 alpha-hydroxyvitamin D3 and calcium.
January 1981, Acta vitaminologica et enzymologica,
S Yoshikawa, and A Ohno, and K Moro, and M Matsumoto, and H Nemoto, and H Seki, and N Kaneko, and O Hosokawa, and H Ishijima
Effect of 1 alpha-hydroxyvitamin D3 on osteoporosis induced by immobilization combined with ovariectomy in rats.
January 1987, Bone,
S Yoshikawa, and A Ohno, and K Moro, and M Matsumoto, and H Nemoto, and H Seki, and N Kaneko, and O Hosokawa, and H Ishijima
Clinical use of 1-alpha-hydroxyvitamin D3.
June 1978, British medical journal,
S Yoshikawa, and A Ohno, and K Moro, and M Matsumoto, and H Nemoto, and H Seki, and N Kaneko, and O Hosokawa, and H Ishijima
[Treatment of hypoparathyroidism with 1 alpha-hydroxyvitamin D3].
June 1990, Zhonghua nei ke za zhi,
S Yoshikawa, and A Ohno, and K Moro, and M Matsumoto, and H Nemoto, and H Seki, and N Kaneko, and O Hosokawa, and H Ishijima
Treatment of pseudohypoparathyroidism with 1 alpha-hydroxyvitamin D3.
January 1980, Contributions to nephrology,
S Yoshikawa, and A Ohno, and K Moro, and M Matsumoto, and H Nemoto, and H Seki, and N Kaneko, and O Hosokawa, and H Ishijima
[Urinary excretion of calcium after administration of 1 alpha-hydroxyvitamin D3 in idiopathic juvenile osteoporosis].
November 1988, Polski tygodnik lekarski (Warsaw, Poland : 1960),
S Yoshikawa, and A Ohno, and K Moro, and M Matsumoto, and H Nemoto, and H Seki, and N Kaneko, and O Hosokawa, and H Ishijima
T lymphocyte subsets in osteoporosis. Effect of 1-alpha hydroxyvitamin D3.
January 1984, Mineral and electrolyte metabolism,
Copied contents to your clipboard!